Cagrilintide
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Novo Nordisk · Phase 1 · Completed · Enrollment 178
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Part A: NNC0174-1213 (SD1-SD5) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part A: Cagrilintide (SDA and SDB) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part A: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: NNC0174-1213 (MD1-MD5) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: Cagrilintide (MDA) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |